Related Experiment Video
Updated: Jul 29, 2025
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
Paraneoplastic or treatment-associated dermatomyositis: a diagnostic challenge
Miguel Esperanca-Martins1, Sara Damaso, Nuno Carreira
1Medical Oncology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal Vascular Biology & Cancer Microenvironment Laboratory, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Portugal Translational Oncobiology Laboratory, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Portugal.
Dermatomyositis (DM) can be a side effect of cancer treatments like paclitaxel. This case study highlights DM developing in a breast cancer patient undergoing chemotherapy.
Area of Science:
- Oncology
- Rheumatology
- Dermatology
Background:
- Dermatomyositis (DM) is an autoimmune disorder with muscle and skin symptoms.
- DM can be a paraneoplastic syndrome in 15-30% of cancer cases.
- Chemotherapy, including taxanes and monoclonal antibodies, can induce DM.
Observation:
- A 35-year-old woman with metastatic breast cancer developed skin lesions.
- The patient had recently started treatment with paclitaxel and anti-HER2 agents.
Findings:
- Clinical, laboratory, and histological data confirmed a diagnosis of DM.
- The DM was likely induced by the prescribed cancer therapies.
Implications:
- This case underscores the importance of recognizing drug-induced DM in cancer patients.
- Awareness of this adverse effect is crucial for managing cancer treatment complications.
- Further research may explore the mechanisms of chemotherapy-induced DM.
Related Concept Videos
01:27Myocarditis II: Clinical Features and Diagnostic Tests
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...